ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis Sells 1,000 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now directly owns 68,624 shares in the company, valued at $4,131,164.80. This trade represents a 1.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Krista Davis also recently made the following trade(s):

• On Wednesday, December 11th, Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $60.00, for a total value of $60,000.00.

ANI Pharmaceuticals Stock Down 1.9 %

Shares of ANIP opened at $54.51 on Wednesday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -99.11 and a beta of 0.74. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.81. The business’s 50 day simple moving average is $57.03 and its 200-day simple moving average is $58.17.

Analyst Ratings Changes

Several equities analysts have recently commented on ANIP shares. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 5th. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Finally, Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $77.71.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of ANI Pharmaceuticals by 41.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company’s stock valued at $2,648,000 after buying an additional 13,948 shares during the period. Stonepine Capital Management LLC purchased a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at $1,128,000. Rafferty Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at $200,000. ProShare Advisors LLC increased its stake in shares of ANI Pharmaceuticals by 29.0% during the fourth quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company’s stock valued at $361,000 after buying an additional 1,469 shares during the period. Finally, Nomura Holdings Inc. increased its stake in shares of ANI Pharmaceuticals by 1.5% during the fourth quarter. Nomura Holdings Inc. now owns 213,879 shares of the specialty pharmaceutical company’s stock valued at $11,823,000 after buying an additional 3,255 shares during the period. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.